• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与良性前列腺增生相关的下尿路症状的实际医疗管理:意大利大量男性人群中5年处方率和住院率的时间趋势

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.

作者信息

Cindolo Luca, Pirozzi Luisella, Fanizza Caterina, Romero Marilena, Sountoulides Petros, Roehrborn Claus G, Mirone Vincenzo, Schips Luigi

机构信息

Department of Urology, "S.Pio da Pietrelcina" Hospital, Vasto, Italy,

出版信息

Int Urol Nephrol. 2014 Apr;46(4):695-701. doi: 10.1007/s11255-013-0587-8. Epub 2013 Oct 18.

DOI:10.1007/s11255-013-0587-8
PMID:24136187
Abstract

PURPOSE

The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system.

METHODS

Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period.

RESULTS

The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively).

CONCLUSIONS

The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.

摘要

目的

本研究旨在利用来自意大利医疗保健系统行政数据库的信息,评估现实临床实践中治疗下尿路症状/良性前列腺增生(LUTS/BPH)的药物处方趋势及住院率。

方法

对约150万名40岁以上男性的处方数据进行检查,计算2004年至2008年连续5年的α受体阻滞剂(ABs)和/或5α还原酶抑制剂(5ARI)的处方盒数。根据年龄计算整个研究期间每种药物类别及联合治疗(CT)的年使用患病率和发病率。同时评估同一时期与LUTS/BPH相关原因的住院率。

结果

就处方盒数而言,治疗LUTS/BPH的药物总体分布增加了43%。两类药物均导致了这种增加,尽管5ARI的增幅大于AB(分别为+49%和+41%)。在≥75岁的患者中,CT的患病率大幅上升至近25%。在研究期间,BPH/LUTS相关原因的住院率下降(非手术和手术原因分别为每年8%和3%)。

结论

治疗LUTS/BPH的药物使用患病率稳步上升。两类药物的处方盒数均有增加,尽管5ARI的增幅更大。住院率的下降需要进一步研究。

相似文献

1
Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.与良性前列腺增生相关的下尿路症状的实际医疗管理:意大利大量男性人群中5年处方率和住院率的时间趋势
Int Urol Nephrol. 2014 Apr;46(4):695-701. doi: 10.1007/s11255-013-0587-8. Epub 2013 Oct 18.
2
Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.药物治疗对良性前列腺增生相关下尿路症状患者的药物依从性和临床结局:基于人群的队列研究。
Eur Urol. 2015 Sep;68(3):418-25. doi: 10.1016/j.eururo.2014.11.006. Epub 2014 Nov 20.
3
A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.一项在欧洲及其他地区进行的、针对良性前列腺增生相关下尿路症状的实际医疗管理的广泛人群研究,该研究超越了官方临床指南。
Eur Urol. 2010 Sep;58(3):450-6. doi: 10.1016/j.eururo.2010.05.045. Epub 2010 Jun 9.
4
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.前列腺素途径在接受药物治疗失败的良性前列腺增生症伴下尿路症状患者中被激活。
Prostate. 2021 Sep;81(13):944-955. doi: 10.1002/pros.24190. Epub 2021 Jul 20.
5
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.良性前列腺增生相关下尿路症状患者的生活质量:根据治疗情况在现实生活中的随时间变化——QUALIPROST研究
Int Urol Nephrol. 2016 May;48(5):645-56. doi: 10.1007/s11255-015-1206-7. Epub 2016 Jan 25.
6
Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?患者对良性前列腺增生(BPH)相关下尿路症状(LUTS)药物治疗的依从性各不相同:联合治疗比单一疗法更好吗?
BMC Urol. 2015 Sep 21;15:96. doi: 10.1186/s12894-015-0090-x.
7
Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.良性前列腺增生相关下尿路症状药物治疗中的药物依从性和药物相关问题。
J Physiol Pharmacol. 2018 Aug;69(4). doi: 10.26402/jpp.2018.4.14. Epub 2018 Dec 9.
8
Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.比较美国良性前列腺增生男性中早期联合使用 α 受体阻滞剂和度他雄胺或非那雄胺治疗的临床和经济结局。
J Manag Care Spec Pharm. 2016 Oct;22(10):1204-14. doi: 10.18553/jmcp.2016.22.10.1204.
9
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.当前良性前列腺增生症的治疗:对性功能的影响及相关性功能不良事件的管理。
Int J Clin Pract. 2011 Sep;65(9):1005-13. doi: 10.1111/j.1742-1241.2011.02731.x. Epub 2011 Jul 1.
10
Risk stratification for benign prostatic hyperplasia (BPH) treatment.良性前列腺增生(BPH)治疗的风险分层。
BJU Int. 2011 Mar;107(6):876-80. doi: 10.1111/j.1464-410X.2010.10041.x. Epub 2011 Jan 25.

引用本文的文献

1
Patient's Perception of the Role of Gym Activity in Abdominal Wall Herniation in Adults: A Prospective Study.患者对健身活动在成人腹壁疝中的作用的认知:一项前瞻性研究。
Sports Med Open. 2024 Aug 13;10(1):88. doi: 10.1186/s40798-024-00749-x.
2
Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea.韩国良性前列腺增生症的患病率及治疗模式变化
Int Neurourol J. 2021 Dec;25(4):347-354. doi: 10.5213/inj.2040412.206. Epub 2021 Jan 27.
3
Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan.

本文引用的文献

1
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.EAU 指南:非神经原性男性下尿路症状(包括良性前列腺梗阻)的治疗和随访。
Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13.
2
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.系统评价非神经原性男性下尿路症状的联合药物治疗。
Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.01.018. Epub 2013 Jan 25.
3
Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
使用 α-1 阻滞剂会增加后续患肾细胞癌的风险:来自台湾的全国性基于人群的研究。
PLoS One. 2020 Nov 19;15(11):e0242429. doi: 10.1371/journal.pone.0242429. eCollection 2020.
4
Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia.α受体阻滞剂治疗下尿路症状/良性前列腺增生的处方模式。
Sci Rep. 2018 Sep 5;8(1):13223. doi: 10.1038/s41598-018-31617-w.
5
Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review.良性前列腺增生(BPE)早期治疗的临床意义:一项系统评价
Curr Urol Rep. 2018 Jul 9;19(9):70. doi: 10.1007/s11934-018-0823-y.
6
Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?长期下尿路症状/良性前列腺增生的药物治疗会改变手术干预的结果吗?
Curr Urol Rep. 2017 Sep;18(9):72. doi: 10.1007/s11934-017-0721-8.
7
A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.荷兰一项针对下尿路症状/良性前列腺增生男性患者使用α受体阻滞剂加抗毒蕈碱联合疗法的治疗持续性和依从性的回顾性研究。
BMC Urol. 2017 May 22;17(1):36. doi: 10.1186/s12894-017-0226-2.
8
5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.5α-还原酶抑制剂疗法可延缓前列腺增生且最大尿流率低于15毫升/秒的患者出现尿潴留及进行前列腺手术的时间。
PLoS One. 2017 Apr 10;12(4):e0175356. doi: 10.1371/journal.pone.0175356. eCollection 2017.
9
Medical management of benign prostatic hyperplasia: Results from a population-based study.良性前列腺增生的医学管理:一项基于人群的研究结果。
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):55-9. doi: 10.5489/cuaj.3058.
10
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.良性前列腺增生相关下尿路症状患者的生活质量:根据治疗情况在现实生活中的随时间变化——QUALIPROST研究
Int Urol Nephrol. 2016 May;48(5):645-56. doi: 10.1007/s11255-015-1206-7. Epub 2016 Jan 25.
临床实践。良性前列腺增生与下尿路症状
N Engl J Med. 2012 Jul 19;367(3):248-57. doi: 10.1056/NEJMcp1106637.
4
Finding pure and simple truths with administrative data.利用行政数据探寻纯粹而简单的真相。
JAMA. 2012 Apr 4;307(13):1433-5. doi: 10.1001/jama.2012.404.
5
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population.泌尿科医生在 Medicare 人群中对良性前列腺增生症的 AUA 最佳实践指南的遵从情况。
Urology. 2011 Jul;78(1):3-9. doi: 10.1016/j.urology.2010.12.087. Epub 2011 May 23.
6
Update on AUA guideline on the management of benign prostatic hyperplasia.美国泌尿外科学会良性前列腺增生管理指南更新。
J Urol. 2011 May;185(5):1793-803. doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.
7
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.联合治疗比单独治疗对前列腺增生(BPH)患者的临床效果:基线特征的 4 年随机、双盲阿夫唑嗪和坦索罗辛联合治疗(CombAT)试验结果。
BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.
8
Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options?下尿路症状提示良性前列腺增生:哪些是高危患者,最佳治疗选择是什么?
Curr Opin Urol. 2011 Jan;21(1):42-8. doi: 10.1097/MOU.0b013e32834100b3.
9
A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.一项在欧洲及其他地区进行的、针对良性前列腺增生相关下尿路症状的实际医疗管理的广泛人群研究,该研究超越了官方临床指南。
Eur Urol. 2010 Sep;58(3):450-6. doi: 10.1016/j.eururo.2010.05.045. Epub 2010 Jun 9.
10
Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society.良性前列腺增生及其相关病症对泌尿科医生、医疗保健系统和社会的相关性。
World J Urol. 2010 Feb;28(1):1-2. doi: 10.1007/s00345-010-0507-9.